Bishoy Faltas, Chief Research Officer at the Englander Institute for Precision Medicine and Associate Professor of Medicine and Cell and Developmental Biology at Weill Cornell Medicine, shared a post on X about a paper he co-authored with colleagues published in Nature Methods:
“ctDNA is a key piece of the puzzle in building an integrated precision oncology ecosystem at Weill Cornell Medicine.
Excited to share collaborative paper #2 this month. This time with the brilliant Alexandre Pellan Cheng, and Dan Landau!
Highlights:
Deep error-corrected WGS of cfDNA using the Ultima Genomics platform.
Tumor-uninformed, ultra-sensitive detection – huge implications for detecting minimal residual disease in Bladder Cancer without tumor sequencing.
Detection of mutational signatures caused by APOBEC3 mutagenic enzymes (SBS2 + SBS13) in cfDNA. These are dominant in bladder cancer and improve test performance.
Detection of chemotherapy-induced signature (SBS31) in cfDNA – even without tumor present, suggesting platinum mutagenesis in nonmalignant cells -> enabling monitoring of chemo-induced genotoxicity.
Beautiful full X-plainer here by Alexandre Pellan Cheng.
Weill Cornell Medicine press release here.
Stay tuned for our next collaborative paper coming soon: another piece of the puzzle…or maybe the key to bringing more pieces together?”
Authors: Alexandre Pellan Cheng, Adam Widman, Anushri Arora, Itai Rusinek, Aaron Sossin, Michael Postow, Nicolas Robine, Bishoy Faltas, Genevieve Boland, Dan Landau et al.
More posts featuring Bishoy Faltas.
